{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T23:46:54Z","timestamp":1794613614400,"version":"4.9.1"},"reference-count":267,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82270233"],"award-info":[{"award-number":["No. 82270233"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82200246"],"award-info":[{"award-number":["No. 82200246"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Guangdong Basic and Applied Basic Research Foundation","award":["2024A1515011659"],"award-info":[{"award-number":["2024A1515011659"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01745-8","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T14:15:05Z","timestamp":1761315305000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies"],"prefix":"10.1186","volume":"18","author":[{"given":"Jingchao","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuojin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinglu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixin","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanfang","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"issue":"6","key":"1745_CR1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20(6):359\u201371.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6382","key":"1745_CR2","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361\u20135.","journal-title":"Science"},{"issue":"3","key":"1745_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185\u201399.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"1745_CR4","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1089\/hum.2017.254","volume":"29","author":"U K\u00f6hl","year":"2018","unstructured":"K\u00f6hl U, Arsenieva S, Holzinger A, Abken H. CAR T cells in trials: recent achievements and challenges that remain in the production of modified T cells for clinical applications. Hum Gene Ther. 2018;29(5):559\u201368.","journal-title":"Hum Gene Ther"},{"issue":"8","key":"1745_CR5","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1182\/blood.2022016204","volume":"141","author":"W Qasim","year":"2023","unstructured":"Qasim W. Genome-edited allogeneic donor universal chimeric antigen receptor T cells. Blood. 2023;141(8):835\u201345.","journal-title":"Blood"},{"issue":"5","key":"1745_CR6","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1111\/trf.14110","volume":"57","author":"A Bersenev","year":"2017","unstructured":"Bersenev A. CAR-T cell manufacturing: time to put it in gear. Transfusion. 2017;57(5):1104\u20136.","journal-title":"Transfusion"},{"issue":"10","key":"1745_CR7","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","volume":"24","author":"M Ruella","year":"2018","unstructured":"Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018;24(10):1499\u2013503.","journal-title":"Nat Med"},{"key":"1745_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1388475","volume":"14","author":"V Moradi","year":"2024","unstructured":"Moradi V, Khodabandehloo E, Alidadi M, Omidkhoda A, Ahmadbeigi N. Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review. Front Oncol. 2024;14:1388475.","journal-title":"Front Oncol"},{"issue":"1","key":"1745_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40164-023-00435-w","volume":"12","author":"C Aparicio","year":"2023","unstructured":"Aparicio C, Acebal C, Gonz\u00e1lez-Vallinas M. Current approaches to develop off-the-shelf chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review. Exp Hematol Oncol. 2023;12(1):73.","journal-title":"Exp Hematol Oncol"},{"issue":"11","key":"1745_CR10","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","volume":"117","author":"ME Flowers","year":"2011","unstructured":"Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117(11):3214\u20139.","journal-title":"Blood"},{"issue":"35","key":"1745_CR11","doi-asserted-by":"publisher","first-page":"5728","DOI":"10.1200\/JCO.2008.17.6545","volume":"26","author":"T Hahn","year":"2008","unstructured":"Hahn T, McCarthy PL Jr., Zhang MJ, Wang D, Arora M, Frangoul H, et al. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol. 2008;26(35):5728\u201334.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1745_CR12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1365-2141.1987.tb06160.x","volume":"67","author":"RP Gale","year":"1987","unstructured":"Gale RP, Bortin MM, van Bekkum DW, et al. Risk factors for acute graft-versus-host disease. Br J Haematol. 1987;67(4):397\u2013406.","journal-title":"Br J Haematol"},{"issue":"1","key":"1745_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-023-00438-1","volume":"9","author":"F Malard","year":"2023","unstructured":"Malard F, Holler E, Sandmaier BM, Huang H, Mohty M. Acute graft-versus-host disease. Nat Rev Dis Primers. 2023;9(1):27.","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"1745_CR14","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1182\/blood.2023020073","volume":"142","author":"O Jamy","year":"2023","unstructured":"Jamy O, Zeiser R, Chen YB. Novel developments in the prophylaxis and treatment of acute GVHD. Blood. 2023;142(12):1037\u201346.","journal-title":"Blood"},{"issue":"1","key":"1745_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, et al. International, multicenter standardization of acute Graft-versus-Host disease clinical data collection: a report from the Mount Sinai acute GVHD international consortium. Biol Blood Marrow Transplant. 2016;22(1):4\u201310.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"22","key":"1745_CR16","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMra1609337","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR. Acute graft-versus-host disease - biologic process, prevention, and therapy. N Engl J Med. 2017;377(22):2167\u201379.","journal-title":"N Engl J Med"},{"issue":"26","key":"1745_CR17","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377(26):2565\u201379.","journal-title":"N Engl J Med"},{"issue":"3","key":"1745_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transpl. 2015;21(3):389\u2013401.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12","key":"1745_CR19","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1182\/blood.2020005185","volume":"136","author":"D Stenger","year":"2020","unstructured":"Stenger D, Stief TA, Kaeuferle T, Willier S, Rataj F, Schober K, et al. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR\/Cas 9-mediated TCR knockout CAR. Blood. 2020;136(12):1407\u201318.","journal-title":"Blood"},{"key":"1745_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2014.21","volume":"1","author":"R Galetto","year":"2014","unstructured":"Galetto R, Lebuhotel C, Poirot L, Gouble A, Toribio ML, Smith J, et al. Pre-TCR\u03b1 supports CD3-dependent reactivation and expansion of TCR\u03b1-deficient primary human T-cells. Mol Ther Methods Clin Dev. 2014;1:14021.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"11","key":"1745_CR21","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1038\/mt.2014.142","volume":"22","author":"M Bunse","year":"2014","unstructured":"Bunse M, Bendle GM, Linnemann, Bies L, Schulz S, Schumacher TN, et al. RNAi-mediated TCR knockdown prevents autoimmunity in mice caused by mixed TCR dimers following TCR gene transfer. Mol Ther. 2014;22(11):1983\u201391.","journal-title":"Mol Ther"},{"issue":"Suppl 1","key":"1745_CR22","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1182\/blood-2021-147738","volume":"138","author":"A-S Al-Homsi","year":"2021","unstructured":"Al-Homsi A-S, Anguille S, Deeren D, Nishihori T, Meuleman N, Abdul-Hay M, et al. Immunicy-1: targeting BCMA with cyad-211 to establish proof of concept of an shrna-based allogeneic CAR t cell therapy platform. Blood. 2021;138(Suppl 1):2817.","journal-title":"Blood"},{"issue":"6481","key":"1745_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367(6481):eaba7365.","journal-title":"Science"},{"issue":"9","key":"1745_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004446","volume":"10","author":"KP Mueller","year":"2022","unstructured":"Mueller KP, Piscopo NJ, Forsberg MH, Saraspe LA, Das A, Russell B, et al. Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression. J Immunother Cancer. 2022;10(9):e004446.","journal-title":"J Immunother Cancer"},{"issue":"668","key":"1745_CR25","doi-asserted-by":"publisher","first-page":"eabq3010","DOI":"10.1126\/scitranslmed.abq3010","volume":"14","author":"G Ottaviano","year":"2022","unstructured":"Ottaviano G, Georgiadis C, Gkazi SA, Syed F, Zhan H, Etuk A, et al. Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. Sci Transl Med. 2022;14(668):eabq3010.","journal-title":"Sci Transl Med"},{"key":"1745_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2023.113491","volume":"517","author":"J Camperi","year":"2023","unstructured":"Camperi J, Devarajan S, McKay A, Tarighat S, Chen D, Hu Z. Assessing TCR identity, knock-in efficiency, and potency for individualized TCR-T cell therapy. J Immunol Methods. 2023;517:113491.","journal-title":"J Immunol Methods"},{"issue":"6","key":"1745_CR27","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382(6):545\u201353.","journal-title":"N Engl J Med"},{"issue":"Suppl 16","key":"1745_CR28","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1200\/JCO.2025.43.16_suppl.2532","volume":"43","author":"XY Zhu","year":"2025","unstructured":"Zhu XY, Sun GY, Pan TZ, Chen XC, Xie HC, Han YS, et al. Prophylactic infusion of allogeneic double-negative T cells as immune modulators to prevent relapse in high-risk AML patients after allo-HSCT: a phase I trial. J Clin Oncol. 2025;43(Suppl 16):2532.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1745_CR29","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1016\/j.cell.2025.03.022","volume":"188","author":"Y Hou","year":"2025","unstructured":"Hou Y, Wu Y, Cao Y, Hu X, Sun Y, Wang H, et al. Optimizing stem cell infusion timing in the prevention of acute graft-versus-host disease. Cell. 2025;188(11):3030\u201344.","journal-title":"Cell"},{"issue":"1","key":"1745_CR30","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40164-025-00654-3","volume":"14","author":"Z Lyu","year":"2025","unstructured":"Lyu Z, Niu S, Fang Y, Chen Y, Li YR, Yang L. Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer. Exp Hematol Oncol. 2025;14(1):66.","journal-title":"Exp Hematol Oncol"},{"issue":"11","key":"1745_CR31","doi-asserted-by":"publisher","DOI":"10.1172\/JCI147683","volume":"131","author":"S Otsuka","year":"2021","unstructured":"Otsuka S, Melis N, Gaida MM, Dutta D, Weigert R, Ashwell JD. Calcineurin inhibitors suppress acute graft-versus-host disease via NFAT-independent inhibition of T cell receptor signaling. J Clin Invest. 2021;131(11):e147683.","journal-title":"J Clin Invest"},{"issue":"2","key":"1745_CR32","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1016\/S2352-3026(19)30220-0","volume":"7","author":"I Walker","year":"2020","unstructured":"Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, et al. Addition of anti-thymocyte Globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2020;7(2):e100\u201311.","journal-title":"Lancet Haematol"},{"key":"1745_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02668","volume":"10","author":"NS Nunes","year":"2019","unstructured":"Nunes NS, Kanakry CG. Mechanisms of graft-versus-host disease prevention by post-transplantation cyclophosphamide: an evolving understanding. Front Immunol. 2019;10:2668.","journal-title":"Front Immunol"},{"issue":"15","key":"1745_CR34","doi-asserted-by":"publisher","DOI":"10.1172\/JCI162201","volume":"133","author":"Y Lin","year":"2023","unstructured":"Lin Y, Gu Q, Lu S, Pan Z, Yang Z, Li Y, et al. Ruxolitinib improves hematopoietic regeneration by restoring mesenchymal stromal cell function in acute graft-versus-host disease. J Clin Invest. 2023;133(15):e162201.","journal-title":"J Clin Invest"},{"issue":"6","key":"1745_CR35","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40259-017-0247-0","volume":"31","author":"M Ruella","year":"2017","unstructured":"Ruella M, Kenderian SS. Next-generation chimeric antigen receptor T-cell therapy: going off the shelf. BioDrugs. 2017;31(6):473\u201381.","journal-title":"BioDrugs"},{"issue":"5","key":"1745_CR36","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11864-023-01061-8","volume":"24","author":"Y An","year":"2023","unstructured":"An Y, Jin X, Zhang H, Zhang M, Mahara S, Lu W, et al. Off-the-Shelf allogeneic CAR cell therapy-neglected HvG effect. Curr Treat Options Oncol. 2023;24(5):409\u201341.","journal-title":"Curr Treat Options Oncol"},{"issue":"6","key":"1745_CR37","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","volume":"18","author":"DL Wagner","year":"2021","unstructured":"Wagner DL, Fritsche E, Pulsipher MA, Ahmed N, Hamieh M, Hegde M, et al. Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol. 2021;18(6):379\u201393.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1745_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41571-024-00959-y","volume":"22","author":"C Diorio","year":"2025","unstructured":"Diorio C, Teachey DT, Grupp SA. Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks. Nat Rev Clin Oncol. 2025;22(1):10\u201327.","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl 1","key":"1745_CR39","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.1182\/blood-2022-169039","volume":"140","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Zhang J, Wang X, Dong W, Yao X, Zhang Y, et al. Allogeneic CAR-T therapy enabled by base editing of Lck to resist dasatinib used to prevent rejection mediated through both T and NK in host. Blood. 2022;140(Suppl 1):4556\u20137.","journal-title":"Blood"},{"key":"1745_CR40","first-page":"157","volume":"333","author":"S Sheldon","year":"2006","unstructured":"Sheldon S, Poulton K. HLA typing and its influence on organ transplantation. Methods Mol Biol (Clifton NJ). 2006;333:157\u201374.","journal-title":"Methods Mol Biol (Clifton NJ)"},{"issue":"2","key":"1745_CR41","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/iji.12527","volume":"48","author":"AM Little","year":"2021","unstructured":"Little AM, Akbarzad-Yousefi A, Anand A, Diaz Burlinson N, Dunn PPJ, Evseeva I, et al. BSHI guideline: HLA matching and donor selection for Haematopoietic progenitor cell transplantation. Int J Immunogenet. 2021;48(2):75\u2013109.","journal-title":"Int J Immunogenet"},{"issue":"8","key":"1745_CR42","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1182\/blood-2013-03-478255","volume":"122","author":"H Torikai","year":"2013","unstructured":"Torikai H, Reik A, Soldner F, Warren EH, Yuen C, Zhou Y, et al. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood. 2013;122(8):1341\u20139.","journal-title":"Blood"},{"issue":"1","key":"1745_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74772-9","volume":"10","author":"J Lee","year":"2020","unstructured":"Lee J, Sheen JH, Lim O, Lee Y, Ryu J, Shin D, et al. Abrogation of HLA surface expression using CRISPR\/Cas 9 genome editing: a step toward universal T cell therapy. Sci Rep. 2020;10(1):17753.","journal-title":"Sci Rep"},{"issue":"10","key":"1745_CR44","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1002\/eji.202049107","volume":"51","author":"Y Guo","year":"2021","unstructured":"Guo Y, Xu B, Wu Z, Bo J, Tong C, Chen D, et al. Mutant B2M-HLA-E and B2M-HLA-G fusion proteins protects universal chimeric antigen receptor-modified T cells from allogeneic NK cell-mediated lysis. Eur J Immunol. 2021;51(10):2513\u201321.","journal-title":"Eur J Immunol"},{"issue":"Suppl 16","key":"1745_CR45","doi-asserted-by":"publisher","first-page":"TPS8063","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8063","volume":"41","author":"JG Berdeja","year":"2023","unstructured":"Berdeja JG, Martin TG, Rossi A, Essell JH, Dicapua Siegel DS, Mailankody S, et al. A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed\/refractory multiple myeloma (CAMMOUFLAGE trial). J Clin Onco. 2023;41(Suppl 16):TPS8063.","journal-title":"J Clin Onco"},{"issue":"4","key":"1745_CR46","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.stem.2019.02.005","volume":"24","author":"H Xu","year":"2019","unstructured":"Xu H, Wang B, Ono M, Kagita A, Fujii K, Sasakawa N, et al. Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility. Cell Stem Cell. 2019;24(4):566\u201378.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"1745_CR47","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00262-023-03586-1","volume":"73","author":"X Chen","year":"2024","unstructured":"Chen X, Tan B, Xing H, Zhao X, Ping Y, Zhang Z, et al. Allogeneic CAR-T cells with of HLA-A\/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies. Cancer Immunol Immunother. 2024;73(1):13.","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"1745_CR48","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1158\/2326-6066.CIR-18-0508","volume":"8","author":"Y Kagoya","year":"2020","unstructured":"Kagoya Y, Guo T, Yeung B, Saso K, Anczurowski M, Wang CH, et al. Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to be used for adoptive T-cell therapy. Cancer Immunol Res. 2020;8(7):926\u201336.","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"1745_CR49","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","volume":"32","author":"Y Hu","year":"2022","unstructured":"Hu Y, Zhou Y, Zhang M, Zhao H, Wei G, Ge W, et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 2022;32(11):995\u20131007.","journal-title":"Cell Res"},{"issue":"2","key":"1745_CR50","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1086\/302519","volume":"65","author":"A DeSandro","year":"1999","unstructured":"DeSandro A, Nagarajan UM, Boss JM. The bare lymphocyte syndrome: molecular clues to the transcriptional regulation of major histocompatibility complex class II genes. Am J Hum Genet. 1999;65(2):279\u201386.","journal-title":"Am J Hum Genet"},{"issue":"11","key":"1745_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100449","volume":"2","author":"YR Li","year":"2021","unstructured":"Li YR, Zhou Y, Kim YJ, Zhu Y, Ma F, Yu J, et al. Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy. Cell Rep Med. 2021;2(11):100449.","journal-title":"Cell Rep Med"},{"issue":"Suppl 1","key":"1745_CR52","doi-asserted-by":"publisher","first-page":"4547","DOI":"10.1182\/blood-2022-167139","volume":"140","author":"AM Williams","year":"2022","unstructured":"Williams AM, Hayama KL, Pan Y, Groff B, Mbofung RM, Chang A, et al. Alloimmune defense receptor harnesses host immune cell activation to potentiate functional persistence and anti-tumor activity of off-the-shelf, cell-based cancer therapy. Blood. 2022;140(Suppl 1):4547\u20138.","journal-title":"Blood"},{"issue":"2","key":"1745_CR53","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","volume":"26","author":"JN Brudno","year":"2020","unstructured":"Brudno JN, Lam N, Vanasse D, Shen YW, Rose JJ, Rossi J, et al. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nat Med. 2020;26(2):270\u201380.","journal-title":"Nat Med"},{"key":"1745_CR54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-150650","volume":"138","author":"Z Zhou","year":"2021","unstructured":"Zhou Z, Han Y, Pan H-B, Sang C-J, Shi D-L, Feng C, et al. Tri-specific CD19xCD20xCD22 VHH CAR-T cells (LCAR-AIO) eradicate antigen-heterogeneous b cell tumors, enhance expansion, and prolong persistence in preclinical in vivo models. Blood. 2021;138:1700.","journal-title":"Blood"},{"key":"1745_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00539","volume":"8","author":"D Schneider","year":"2018","unstructured":"Schneider D, Xiong Y, Hu P, Wu D, Chen W, Ying T, et al. A unique human immunoglobulin heavy chain variable domain-only CD33 CAR for the treatment of acute myeloid leukemia. Front Oncol. 2018;8:539.","journal-title":"Front Oncol"},{"issue":"1","key":"1745_CR56","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","volume":"21","author":"A Dimitri","year":"2022","unstructured":"Dimitri A, Herbst F, Fraietta JA. Engineering the next-generation of CAR T-cells with CRISPR-Cas 9 gene editing. Mol Cancer. 2022;21(1):78.","journal-title":"Mol Cancer"},{"issue":"11","key":"1745_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23115992","volume":"23","author":"SA Smirnikhina","year":"2022","unstructured":"Smirnikhina SA, Zaynitdinova MI, Sergeeva VA, Lavrov AV. Improving homology-directed repair in genome editing experiments by influencing the cell cycle. Int J Mol Sci. 2022;23(11):5992.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1745_CR58","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw064","volume":"44","author":"X He","year":"2016","unstructured":"He X, Tan C, Wang F, Wang Y, Zhou R, Cui D, et al. Knock-in of large reporter genes in human cells via CRISPR\/Cas 9-induced homology-dependent and independent DNA repair. Nucleic Acids Res. 2016;44(9):e85.","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"1745_CR59","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016428","volume":"6","author":"A Mehta","year":"2014","unstructured":"Mehta A, Haber JE. Sources of DNA double-strand breaks and models of recombinational DNA repair. Cold Spring Harb Perspect Biol. 2014;6(9):a016428.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"5","key":"1745_CR60","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a012757","volume":"5","author":"KK Chiruvella","year":"2013","unstructured":"Chiruvella KK, Liang Z, Wilson TE. Repair of double-strand breaks by end joining. Cold Spring Harb Perspect Biol. 2013;5(5):a012757.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"1745_CR61","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/nmeth.1539","volume":"8","author":"Y Doyon","year":"2011","unstructured":"Doyon Y, Vo TD, Mendel MC, Greenberg SG, Wang J, Xia DF, et al. Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures. Nat Methods. 2011;8(1):74\u20139.","journal-title":"Nat Methods"},{"issue":"9","key":"1745_CR62","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/nrg2842","volume":"11","author":"FD Urnov","year":"2010","unstructured":"Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. Nat Rev Genet. 2010;11(9):636\u201346.","journal-title":"Nat Rev Genet"},{"issue":"8","key":"1745_CR63","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nbt1125","volume":"23","author":"MH Porteus","year":"2005","unstructured":"Porteus MH, Carroll D. Gene targeting using zinc finger nucleases. Nat Biotechnol. 2005;23(8):967\u201373.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"1745_CR64","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nbt.1755","volume":"29","author":"JC Miller","year":"2011","unstructured":"Miller JC, Tan S, Qiao G, Barlow KA, Wang J, Xia DF, et al. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol. 2011;29(2):143\u20138.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"1745_CR65","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/mt.2015.197","volume":"24","author":"MJ Osborn","year":"2016","unstructured":"Osborn MJ, Webber BR, Knipping F, Lonetree CL, Tennis N, DeFeo AP, et al. Evaluation of TCR gene editing achieved by TALENs, CRISPR\/Cas 9, and MegaTAL nucleases. Mol Ther. 2016;24(3):570\u201381.","journal-title":"Mol Ther"},{"issue":"1","key":"1745_CR66","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrm3486","volume":"14","author":"JK Joung","year":"2013","unstructured":"Joung JK, Sander JD. TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol. 2013;14(1):49\u201355.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6051","key":"1745_CR67","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1126\/science.1204094","volume":"333","author":"AJ Bogdanove","year":"2011","unstructured":"Bogdanove AJ, Voytas DF. TAL effectors: customizable proteins for DNA targeting. Science. 2011;333(6051):1843\u20136.","journal-title":"Science"},{"issue":"10","key":"1745_CR68","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1172\/JCI72992","volume":"124","author":"RM Gupta","year":"2014","unstructured":"Gupta RM, Musunuru K. Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas 9. J Clin Invest. 2014;124(10):4154\u201361.","journal-title":"J Clin Invest"},{"key":"1745_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4447","volume":"5","author":"A Richter","year":"2014","unstructured":"Richter A, Streubel J, Bl\u00fccher C, Szurek B, Reschke M, Grau J, et al. A TAL effector repeat architecture for frameshift binding. Nat Commun. 2014;5:3447.","journal-title":"Nat Commun"},{"issue":"12","key":"1745_CR70","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a023754","volume":"8","author":"T Gaj","year":"2016","unstructured":"Gaj T, Sirk SJ, Shui SL, Liu J. Genome-editing technologies: principles and applications. Cold Spring Harb Perspect Biol. 2016;8(12):a023754.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"1745_CR71","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2174\/156652311794520111","volume":"11","author":"G Silva","year":"2011","unstructured":"Silva G, Poirot L, Galetto R, Smith J, Montoya G, Duchateau P, P\u00e2ques F. Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy. Curr Gene Ther. 2011;11(1):11\u201327.","journal-title":"Curr Gene Ther"},{"issue":"13","key":"1745_CR72","doi-asserted-by":"publisher","first-page":"6367","DOI":"10.1093\/nar\/gks268","volume":"40","author":"F Daboussi","year":"2012","unstructured":"Daboussi F, Zaslavskiy M, Poirot L, Loperfido M, Gouble A, Guyot V, et al. Chromosomal context and epigenetic mechanisms control the efficacy of genome editing by rare-cutting designer endonucleases. Nucleic Acids Res. 2012;40(13):6367\u201379.","journal-title":"Nucleic Acids Res"},{"issue":"36","key":"1745_CR73","doi-asserted-by":"publisher","first-page":"30139","DOI":"10.1074\/jbc.M112.379966","volume":"287","author":"J Valton","year":"2012","unstructured":"Valton J, Daboussi F, Leduc S, Molina R, Redondo P, Macmaster R, et al. 5\u2019-cytosine-phosphoguanine (CpG) methylation impacts the activity of natural and engineered meganucleases. J Biol Chem. 2012;287(36):30139\u201350.","journal-title":"J Biol Chem"},{"issue":"4","key":"1745_CR74","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1093\/nar\/gkt1224","volume":"42","author":"S Boissel","year":"2014","unstructured":"Boissel S, Jarjour J, Astrakhan A, Adey A, Gouble A, Duchateau P, et al. Megatals: a rare-cleaving nuclease architecture for therapeutic genome engineering. Nucleic Acids Res. 2014;42(4):2591\u2013601.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"1745_CR75","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.1073\/pnas.1321030111","volume":"111","author":"R Takeuchi","year":"2014","unstructured":"Takeuchi R, Choi M, Stoddard BL. Redesign of extensive protein-DNA interfaces of meganucleases using iterative cycles of in vitro compartmentalization. Proc Natl Acad Sci U S A. 2014;111(11):4061\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1745_CR76","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1038\/s41467-021-23561-7","volume":"12","author":"U Zekonyte","year":"2021","unstructured":"Zekonyte U, Bacman SR, Smith J, Shoop W, Pereira CV, Tomberlin G, et al. Mitochondrial targeted meganuclease as a platform to eliminate mutant MtDNA in vivo. Nat Commun. 2021;12(1):3210.","journal-title":"Nat Commun"},{"issue":"9","key":"1745_CR77","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1016\/j.ymthe.2022.05.013","volume":"30","author":"CL Gorsuch","year":"2022","unstructured":"Gorsuch CL, Nemec P, Yu M, Xu S, Han D, Smith J, et al. Targeting the hepatitis B CccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivo. Mol Ther. 2022;30(9):2909\u201322.","journal-title":"Mol Ther"},{"issue":"6096","key":"1745_CR78","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816\u201321.","journal-title":"Science"},{"issue":"5962","key":"1745_CR79","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1126\/science.1179555","volume":"327","author":"P Horvath","year":"2010","unstructured":"Horvath P, Barrangou R. CRISPR\/Cas, the immune system of bacteria and archaea. Science. 2010;327(5962):167\u201370.","journal-title":"Science"},{"issue":"6176","key":"1745_CR80","doi-asserted-by":"publisher","DOI":"10.1126\/science.1247997","volume":"343","author":"M Jinek","year":"2014","unstructured":"Jinek M, Jiang F, Taylor DW, Sternberg SH, Kaya E, Ma E, et al. Structures of Cas9 endonucleases reveal RNA-mediated conformational activation. Science. 2014;343(6176):1247997.","journal-title":"Science"},{"issue":"5","key":"1745_CR81","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.cell.2014.02.001","volume":"156","author":"H Nishimasu","year":"2014","unstructured":"]Nishimasu H, Ran FA, Hsu PD, Konermann S, Shehata SI, Dohmae N, et al. Crystal structure of Cas 9 in complex with guide RNA and target DNA. Cell. 2014;156(5):935\u201349.","journal-title":"Cell"},{"issue":"8","key":"1745_CR82","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.4192","volume":"36","author":"M Kosicki","year":"2018","unstructured":"Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPR-Cas 9 leads to large deletions and complex rearrangements. Nat Biotechnol. 2018;36(8):765\u201371.","journal-title":"Nat Biotechnol"},{"issue":"7","key":"1745_CR83","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","volume":"24","author":"E Haapaniemi","year":"2018","unstructured":"Haapaniemi E, Botla S, Persson J, Schmierer B, Taipale J. CRISPR-Cas 9 genome editing induces a p53-mediated DNA damage response. Nat Med. 2018;24(7):927\u201330.","journal-title":"Nat Med"},{"issue":"7","key":"1745_CR84","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s41591-018-0050-6","volume":"24","author":"RJ Ihry","year":"2018","unstructured":"Ihry RJ, Worringer KA, Salick MR, Frias E, Ho D, Theriault K, et al. P53 inhibits CRISPR-Cas 9 engineering in human pluripotent stem cells. Nat Med. 2018;24(7):939\u201346.","journal-title":"Nat Med"},{"issue":"1","key":"1745_CR85","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nbt.3081","volume":"33","author":"JA Zuris","year":"2015","unstructured":"Zuris JA, Thompson DB, Shu Y, Guilinger JP, Bessen JL, Hu JH, et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat Biotechnol. 2015;33(1):73\u201380.","journal-title":"Nat Biotechnol"},{"key":"1745_CR86","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.04766","volume":"3","author":"S Lin","year":"2014","unstructured":"Lin S, Staahl BT, Alla RK, Doudna JA. Enhanced homology-directed human genome engineering by controlled timing of CRISPR\/Cas 9 delivery. Elife. 2014;3:e04766.","journal-title":"Elife"},{"issue":"6","key":"1745_CR87","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1101\/gr.171322.113","volume":"24","author":"S Kim","year":"2014","unstructured":"Kim S, Kim D, Cho SW, Kim J, Kim JS. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas 9 ribonucleoproteins. Genome Res. 2014;24(6):1012\u20139.","journal-title":"Genome Res"},{"issue":"6","key":"1745_CR88","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.cell.2013.08.021","volume":"154","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE, et al. Double nicking by RNA-guided CRISPR Cas 9 for enhanced genome editing specificity. Cell. 2013;154(6):1380\u20139.","journal-title":"Cell"},{"key":"1745_CR89","doi-asserted-by":"publisher","first-page":"15","DOI":"10.21775\/cimb.026.015","volume":"26","author":"DJW Brocken","year":"2018","unstructured":"Brocken DJW, Tark-Dame M, Dame RT. dCas 9: a versatile tool for epigenome editing. Curr Issues Mol Biol. 2018;26:15\u201332.","journal-title":"Curr Issues Mol Biol"},{"issue":"21","key":"1745_CR90","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1182\/blood-2016-01-678136","volume":"127","author":"DB Kohn","year":"2016","unstructured":"Kohn DB, Porteus MH, Scharenberg AM. Ethical and regulatory aspects of genome editing. Blood. 2016;127(21):2553\u201360.","journal-title":"Blood"},{"issue":"21","key":"1745_CR91","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1021\/acs.biochem.8b00107","volume":"57","author":"ZJ Kartje","year":"2018","unstructured":"Kartje ZJ, Barkau CL, Rohilla KJ, Ageely EA, Gagnon KT. Chimeric guides probe and enhance Cas 9 biochemical activity. Biochemistry. 2018;57(21):3027\u201331.","journal-title":"Biochemistry"},{"issue":"3","key":"1745_CR92","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nchembio.2559","volume":"14","author":"H Yin","year":"2018","unstructured":"Yin H, Song CQ, Suresh S, Kwan SY, Wu Q, Walsh S, et al. Partial DNA-guided Cas 9 enables genome editing with reduced off-target activity. Nat Chem Biol. 2018;14(3):311\u20136.","journal-title":"Nat Chem Biol"},{"issue":"3","key":"1745_CR93","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.cell.2015.09.038","volume":"163","author":"B Zetsche","year":"2015","unstructured":"Zetsche B, Gootenberg JS, Abudayyeh OO, Slaymaker IM, Makarova KS, Essletzbichler P, et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell. 2015;163(3):759\u201371.","journal-title":"Cell"},{"issue":"2","key":"1745_CR94","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.molcel.2017.03.016","volume":"66","author":"DC Swarts","year":"2017","unstructured":"Swarts DC, van der Oost J, Jinek M. Structural basis for guide RNA processing and Seed-Dependent DNA targeting by CRISPR-Cas12a. Mol Cell. 2017;66(2):221\u201333.","journal-title":"Mol Cell"},{"issue":"9","key":"1745_CR95","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1111\/pbi.14100","volume":"21","author":"L Tripathi","year":"2023","unstructured":"Tripathi L, Ntui VO, Tripathi JN, Norman D, Crawford J. A new and novel high-fidelity genome editing tool for banana using Cas-CLOVER. Plant Biotechnol J. 2023;21(9):1731\u20133.","journal-title":"Plant Biotechnol J"},{"key":"1745_CR96","first-page":"979","volume":"29","author":"BB Madison","year":"2022","unstructured":"Madison BB, Patil D, Richter M, Li X, Tong M, Cranert S, et al. Cas-CLOVER is a novel high-fidelity nuclease for safe and robust generation of TSCM-enriched allogeneic CAR-T cells. Mol Ther. 2022;29:979\u201395.","journal-title":"Mol Ther"},{"issue":"7603","key":"1745_CR97","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","volume":"533","author":"AC Komor","year":"2016","unstructured":"Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016;533(7603):420\u20134.","journal-title":"Nature"},{"issue":"10","key":"1745_CR98","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2300709","volume":"389","author":"R Chiesa","year":"2023","unstructured":"Chiesa R, Georgiadis C, Syed F, Zhan H, Etuk A, Gkazi SA, et al. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N Engl J Med. 2023;389(10):899\u2013910.","journal-title":"N Engl J Med"},{"issue":"6","key":"1745_CR99","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.molcel.2017.08.008","volume":"67","author":"P Billon","year":"2017","unstructured":"Billon P, Bryant EE, Joseph SA, Nambiar TS, Hayward SB, Rothstein R, et al. CRISPR-Mediated base editing enables efficient disruption of eukaryotic genes through induction of STOP codons. Mol Cell. 2017;67(6):1068\u201379.","journal-title":"Mol Cell"},{"issue":"1","key":"1745_CR100","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00294-021-01211-1","volume":"68","author":"YS Slesarenko","year":"2022","unstructured":"Slesarenko YS, Lavrov AV, Smirnikhina SA. Off-target effects of base editors: what we know and how we can reduce it. Curr Genet. 2022;68(1):39\u201348.","journal-title":"Curr Genet"},{"issue":"7785","key":"1745_CR101","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576(7785):149\u201357.","journal-title":"Nature"},{"issue":"12","key":"1745_CR102","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41587-023-02095-x","volume":"42","author":"R Liang","year":"2024","unstructured":"Liang R, He Z, Zhao KT, Zhu H, Hu J, Liu G, et al. Prime editing using CRISPR-Cas12a and circular RNAs in human cells. Nat Biotechnol. 2024;42(12):1867\u201375.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"1745_CR103","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41576-022-00541-1","volume":"24","author":"PJ Chen","year":"2023","unstructured":"Chen PJ, Liu DR. Prime editing for precise and highly versatile genome manipulation. Nat Rev Genet. 2023;24(3):161\u201377.","journal-title":"Nat Rev Genet"},{"issue":"9","key":"1745_CR104","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nbt.2623","volume":"31","author":"Y Fu","year":"2013","unstructured":"Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol. 2013;31(9):822\u20136.","journal-title":"Nat Biotechnol"},{"issue":"6268","key":"1745_CR105","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.aad5227","volume":"351","author":"IM Slaymaker","year":"2016","unstructured":"Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F. Rationally engineered Cas 9 nucleases with improved specificity. Science. 2016;351(6268):84\u20138.","journal-title":"Science"},{"issue":"7","key":"1745_CR106","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","volume":"31","author":"T Gaj","year":"2013","unstructured":"Gaj T, Gersbach CA, Barbas CF. ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering. Trends Biotechnol. 2013;31(7):397\u2013405.","journal-title":"Trends Biotechnol"},{"key":"1745_CR107","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.exphem.2022.03.002","volume":"110","author":"W Wen","year":"2022","unstructured":"Wen W, Zhang XB. Crispr-Cas 9 gene editing induced complex on-target outcomes in human cells. Exp Hematol. 2022;110:13\u20139.","journal-title":"Exp Hematol"},{"issue":"11","key":"1745_CR108","doi-asserted-by":"publisher","first-page":"e833","DOI":"10.1016\/S2352-3026(22)00245-9","volume":"9","author":"R Benjamin","year":"2022","unstructured":"Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, et al. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. Lancet Haematol. 2022;9(11):e833\u201343.","journal-title":"Lancet Haematol"},{"issue":"4","key":"1745_CR109","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nmeth.2857","volume":"11","author":"B Shen","year":"2014","unstructured":"Shen B, Zhang W, Zhang J, Zhou J, Wang J, Chen L, et al. Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat Methods. 2014;11(4):399\u2013402.","journal-title":"Nat Methods"},{"issue":"12","key":"1745_CR110","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","volume":"19","author":"HA Rees","year":"2018","unstructured":"Rees HA, Liu DR. Base editing: precision chemistry on the genome and transcriptome of living cells. Nat Rev Genet. 2018;19(12):770\u201388.","journal-title":"Nat Rev Genet"},{"issue":"6","key":"1745_CR111","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1182\/blood.2022015825","volume":"140","author":"C Diorio","year":"2022","unstructured":"Diorio C, Murray R, Naniong M, Barrera L, Camblin A, Chukinas J, et al. Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL. Blood. 2022;140(6):619\u201329.","journal-title":"Blood"},{"issue":"5","key":"1745_CR112","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s41551-023-01011-7","volume":"7","author":"M Kawamata","year":"2023","unstructured":"Kawamata M, Suzuki HI, Kimura R, Suzuki A. Optimization of Cas9 activity through the addition of cytosine extensions to single-guide RNAs. Nat Biomed Eng. 2023;7(5):672\u201391.","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"1745_CR113","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41592-024-02502-4","volume":"22","author":"A Cirincione","year":"2025","unstructured":"Cirincione A, Simpson D, Yan W, McNulty R, Ravisankar P, Solley SC, et al. A benchmarked, high-efficiency prime editing platform for multiplexed dropout screening. Nat Methods. 2025;22(1):92\u2013101.","journal-title":"Nat Methods"},{"issue":"10266","key":"1745_CR114","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","volume":"396","author":"R Benjamin","year":"2020","unstructured":"Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G, et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet. 2020;396(10266):1885\u201394.","journal-title":"Lancet"},{"issue":"1","key":"1745_CR115","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/imr.12137","volume":"257","author":"H Singh","year":"2014","unstructured":"Singh H, Huls H, Kebriaei P, Cooper LJ. A new approach to gene therapy using sleeping beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev. 2014;257(1):181\u201390.","journal-title":"Immunol Rev"},{"issue":"374","key":"1745_CR116","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj2013","volume":"9","author":"W Qasim","year":"2017","unstructured":"Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017;9(374):eaaj2013.","journal-title":"Sci Transl Med"},{"issue":"6","key":"1745_CR117","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1016\/j.ymthe.2024.11.035","volume":"33","author":"YR Li","year":"2025","unstructured":"Li YR, Fang Y, Niu S, Chen Y, Lyu Z, Yang L. Managing allorejection in off-the-shelf CAR-engineered cell therapies. Mol Ther. 2025;33(6):2368\u201390.","journal-title":"Mol Ther"},{"issue":"12","key":"1745_CR118","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1038\/s43018-024-00867-1","volume":"5","author":"C Gr\u00e9goire","year":"2024","unstructured":"Gr\u00e9goire C, Melenhorst JJ. Navigating CAR-T cell therapy long-term complications. Nat Cancer. 2024;5(12):1768\u201370.","journal-title":"Nat Cancer"},{"issue":"4","key":"1745_CR119","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/cyto.b.21880","volume":"98","author":"E Maryamchik","year":"2020","unstructured":"Maryamchik E, Gallagher KME, Preffer FI, Kadauke S, Maus MV. New directions in chimeric antigen receptor T cell [CAR-T] therapy and related flow cytometry. Cytometry B Clin Cytom. 2020;98(4):299\u2013327.","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"1745_CR120","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/cyto.b.21891","volume":"100","author":"G Sarikonda","year":"2021","unstructured":"Sarikonda G, Pahuja A, Kalfoglou C, Burns K, Nguyen K, Ch\u2019 IL, et al. Monitoring CAR-T cell kinetics in clinical trials by multiparametric flow cytometry: benefits and challenges. Cytometry B Clin Cytom. 2021;100(1):72\u20138.","journal-title":"Cytometry B Clin Cytom"},{"issue":"5","key":"1745_CR121","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41587-024-02307-y","volume":"43","author":"M Zhu","year":"2025","unstructured":"Zhu M, Xu R, Yuan J, Wang J, Ren X, Cong T, et al. Tracking-seq reveals the heterogeneity of off-target effects in CRISPR-Cas9-mediated genome editing. Nat Biotechnol. 2025;43(5):799\u2013810.","journal-title":"Nat Biotechnol"},{"issue":"6437","key":"1745_CR122","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1126\/science.aav9023","volume":"364","author":"B Wienert","year":"2019","unstructured":"Wienert B, Wyman SK, Richardson CD, Yeh CD, Akcakaya P, Porritt MJ, et al. Unbiased detection of CRISPR off-targets in vivo using DISCOVER-Seq. Science. 2019;364(6437):286\u20139.","journal-title":"Science"},{"issue":"1","key":"1745_CR123","doi-asserted-by":"publisher","first-page":"7545","DOI":"10.1038\/s41467-022-35086-8","volume":"13","author":"Z Yu","year":"2022","unstructured":"Yu Z, Lu Z, Li J, Wang Y, Wu P, Li Y, et al. PEAC-seq adopts prime editor to detect CRISPR off-target and DNA translocation. Nat Commun. 2022;13(1):7545.","journal-title":"Nat Commun"},{"issue":"6","key":"1745_CR124","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00439-023-02561-1","volume":"142","author":"JMT Hunt","year":"2023","unstructured":"Hunt JMT, Samson CA, Rand AD, Sheppard HM. Unintended CRISPR-Cas 9 editing outcomes: a review of the detection and prevalence of structural variants generated by gene-editing in human cells. Hum Genet. 2023;142(6):705\u201320.","journal-title":"Hum Genet"},{"issue":"1","key":"1745_CR125","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12943-023-01783-1","volume":"22","author":"S Huang","year":"2023","unstructured":"Huang S, Wang X, Wang Y, Wang Y, Fang C, Wang Y, et al. Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies. Mol Cancer. 2023;22(1):80.","journal-title":"Mol Cancer"},{"issue":"1","key":"1745_CR126","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13059-020-1926-6","volume":"21","author":"D L\u00e4hnemann","year":"2020","unstructured":"L\u00e4hnemann D, K\u00f6ster J, Szczurek E, McCarthy DJ, Hicks SC, Robinson MD, et al. Eleven grand challenges in single-cell data science. Genome Biol. 2020;21(1):31.","journal-title":"Genome Biol"},{"key":"1745_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102684","volume":"73","author":"J Shen","year":"2024","unstructured":"Shen J, Hu R, Lin A, Jiang A, Tang B, Liu Z, et al. Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and vigibase. EClinicalMedicine. 2024;73:102684.","journal-title":"EClinicalMedicine"},{"issue":"10","key":"1745_CR128","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","volume":"34","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Somerville RP, Shi V, Rose JJ, Halverson DC, Fowler DH, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016;34(10):1112\u201321.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1745_CR129","doi-asserted-by":"publisher","DOI":"10.3390\/cells10102631","volume":"10","author":"N Boyd","year":"2021","unstructured":"Boyd N, Cartledge K, Cao H, Evtimov V, Pupovac A, Trounson A, et al. Off-the-shelf\u2019 immunotherapy: manufacture of CD8\u2009+\u2009T cells derived from hematopoietic stem cells. Cells. 2021;10(10):2631.","journal-title":"Cells"},{"issue":"1","key":"1745_CR130","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/trf.14365","volume":"58","author":"J Kwoczek","year":"2018","unstructured":"Kwoczek J, Riese SB, Tischer S, Bak S, Lahrberg J, Oelke M, et al. Cord blood-derived T cells allow the generation of a more na\u00efve tumor-reactive cytotoxic T-cell phenotype. Transfusion. 2018;58(1):88\u201399.","journal-title":"Transfusion"},{"issue":"9","key":"1745_CR131","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1182\/blood.V94.9.3101","volume":"94","author":"S Kadereit","year":"1999","unstructured":"Kadereit S, Mohammad SF, Miller RE, Woods KD, Listrom CD, McKinnon K, et al. Reduced NFAT1 protein expression in human umbilical cord blood T lymphocytes. Blood. 1999;94(9):3101\u20137.","journal-title":"Blood"},{"issue":"7","key":"1745_CR132","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S1470-2045(10)70127-3","volume":"11","author":"M Eapen","year":"2010","unstructured":"Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010;11(7):653\u201360.","journal-title":"Lancet Oncol"},{"issue":"26","key":"1745_CR133","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1182\/blood-2015-06-654780","volume":"126","author":"P Hiwarkar","year":"2015","unstructured":"Hiwarkar P, Qasim W, Ricciardelli I, Gilmour K, Quezada S, Saudemont A, et al. Cord blood T cells mediate enhanced antitumor effects compared with adult peripheral blood T cells. Blood. 2015;126(26):2882\u201391.","journal-title":"Blood"},{"issue":"9\u201310","key":"1745_CR134","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s10354-012-0070-7","volume":"162","author":"H Juch","year":"2012","unstructured":"Juch H, Blaschitz A, Dohr G, Hutter H. HLA class I expression in the human placenta. Wien Med Wochenschr. 2012;162(9\u201310):196\u2013200.","journal-title":"Wien Med Wochenschr"},{"issue":"4","key":"1745_CR135","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.stem.2022.02.009","volume":"29","author":"Z Wang","year":"2022","unstructured":"Wang Z, McWilliams-Koeppen HP, Reza H, Ostberg JR, Chen W, Wang X, et al. 3D-organoid culture supports differentiation of human CAR\u2009+\u2009iPSCs into highly functional CAR T cells. Cell Stem Cell. 2022;29(4):515\u201327.","journal-title":"Cell Stem Cell"},{"issue":"10","key":"1745_CR136","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nbt.2678","volume":"31","author":"M Themeli","year":"2013","unstructured":"Themeli M, Kloss CC, Ciriello G, Fedorov VD, Perna F, Gonen M, Sadelain M. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol. 2013;31(10):928\u201333.","journal-title":"Nat Biotechnol"},{"issue":"Suppl 1","key":"1745_CR137","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1182\/blood-2023-173356","volume":"142","author":"Y Hattori","year":"2023","unstructured":"Hattori Y, Kubo T, Nagano S, Miyama T, Taniguchi Y, Iba Y, et al. Anti-CD38-CAR IPS-derived cytotoxic T lymphocytes efficiently eliminate myeloma cells treated with daratumumab and isatuximab in vitro and in vivo. Blood. 2023;142(Suppl 1):3312.","journal-title":"Blood"},{"key":"1745_CR138","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3389\/fimmu.2020.00888","volume":"11","author":"M Cerrano","year":"2020","unstructured":"Cerrano M, Ruella M, Perales MA, Vitale C, Faraci DG, Giaccone L, et al. The advent of CAR T-cell therapy for lymphoproliferative neoplasms: integrating research into clinical practice. Front Immunol. 2020;11:888.","journal-title":"Front Immunol"},{"issue":"1","key":"1745_CR139","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s13287-019-1455-y","volume":"10","author":"S Moradi","year":"2019","unstructured":"Moradi S, Mahdizadeh H, \u0160ari\u0107 T, Kim J, Harati J, Shahsavarani H, et al. Research and therapy with induced pluripotent stem cells (iPSCs): social, legal, and ethical considerations. Stem Cell Res Ther. 2019;10(1):341.","journal-title":"Stem Cell Res Ther"},{"key":"1745_CR140","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.588453","volume":"7","author":"RE Burnham","year":"2020","unstructured":"Burnham RE, Zoine JT, Story JY, Garimalla SN, Gibson G, Rae A, et al. Characterization of donor variability for \u03b3\u03b4 T cell ex vivo expansion and development of an allogeneic \u03b3\u03b4 T cell immunotherapy. Front Med. 2020;7:588453.","journal-title":"Front Med"},{"issue":"1","key":"1745_CR141","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","volume":"16","author":"P Zhang","year":"2023","unstructured":"Zhang P, Zhang G, Wan X. Challenges and new technologies in adoptive cell therapy. J Hematol Oncol. 2023;16(1):97.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"1745_CR142","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/eji.1830210429","volume":"21","author":"K Deusch","year":"1991","unstructured":"Deusch K, L\u00fcling F, Reich K, Classen M, Wagner H, Pfeffer K. A major fraction of human intraepithelial lymphocytes simultaneously expresses the gamma\/delta T cell receptor, the CD8 accessory molecule and preferentially uses the V delta 1 gene segment. Eur J Immunol. 1991;21(4):1053\u20139.","journal-title":"Eur J Immunol"},{"issue":"1","key":"1745_CR143","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/j.1365-2249.1994.tb06610.x","volume":"98","author":"MC Falk","year":"1994","unstructured":"Falk MC, Ng G, Zhang GY, Fanning GC, Kamath KR, Knight JF. Predominance of T cell receptor V delta 3 in small bowel biopsies from coeliac disease patients. Clin Exp Immunol. 1994;98(1):78\u201382.","journal-title":"Clin Exp Immunol"},{"key":"1745_CR144","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.3389\/fimmu.2018.01367","volume":"9","author":"GM Siegers","year":"2018","unstructured":"Siegers GM, Dutta I, Lai R, Postovit LM. Functional plasticity of gamma delta T cells and breast tumor targets in hypoxia. Front Immunol. 2018;9:1367.","journal-title":"Front Immunol"},{"key":"1745_CR145","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01395","volume":"9","author":"E Lo Presti","year":"2018","unstructured":"Lo Presti E, Pizzolato G, Corsale AM, Caccamo N, Sireci G, Dieli F, et al. \u03b3\u03b4 T cells and tumor microenvironment: from immunosurveillance to tumor evasion. Front Immunol. 2018;9:1395.","journal-title":"Front Immunol"},{"issue":"2","key":"1745_CR146","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ymthe.2017.12.001","volume":"26","author":"A Capsomidis","year":"2018","unstructured":"Capsomidis A, Benthall G, Van Acker HH, Fisher J, Kramer AM, Abeln Z, et al. Chimeric antigen Receptor-engineered human gamma delta T cells: enhanced cytotoxicity with retention of cross presentation. Mol Ther. 2018;26(2):354\u201365.","journal-title":"Mol Ther"},{"issue":"7","key":"1745_CR147","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41568-019-0153-5","volume":"19","author":"B Silva-Santos","year":"2019","unstructured":"Silva-Santos B, Mensurado S, Coffelt SB. \u0393\u03b4 t cells: pleiotropic immune effectors with therapeutic potential in cancer. Nat Rev Cancer. 2019;19(7):392\u2013404.","journal-title":"Nat Rev Cancer"},{"issue":"Suppl 1","key":"1745_CR148","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1182\/blood-2021-149095","volume":"138","author":"MA Wallet","year":"2021","unstructured":"Wallet MA, Nishimura T, Del Casale C, Lebid A, Salantes B, Santostefano K, et al. Induced pluripotent stem cell-derived gamma delta CAR-T cells for cancer immunotherapy. Blood. 2021;138(Suppl 1):2771.","journal-title":"Blood"},{"issue":"suppl 16","key":"1745_CR149","doi-asserted-by":"publisher","first-page":"7509","DOI":"10.1200\/JCO.2022.40.16_suppl.7509","volume":"40","author":"SS Neelapu","year":"2022","unstructured":"Neelapu SS, Hamadani M, Miklos DB, Holmes H, Hinkle J, Kennedy-Wilde J, et al. A phase 1 study of ADI-001: anti-CD20 CAR-engineered allogeneic gamma delta (\u03b3\u03b4) T cells in adults with B-cell malignancies. J Clin Oncol. 2022;40(suppl 16):7509.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"1745_CR150","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1182\/blood-2023-181919","volume":"142","author":"MA Moreno","year":"2023","unstructured":"Moreno MA, Kennedy-Wilde J, Wrong AD, Jahchan N, Galimi F, Ye Y, et al. Expansion, persistence and pharmacodynamic profile of ADI-001, a first-in-class allogeneic CD20-targeted CAR gamma delta T cell therapy, in patients with relapsed\/refractory aggressive B-cell non-Hodgkin\u2019s lymphoma. Blood. 2023;142(Suppl 1):3478.","journal-title":"Blood"},{"issue":"1","key":"1745_CR151","doi-asserted-by":"publisher","first-page":"6942","DOI":"10.1038\/s41467-023-42619-2","volume":"14","author":"D Lee","year":"2023","unstructured":"Lee D, Dunn ZS, Guo W, Rosenthal CJ, Penn NE, Yu Y, et al. Unlocking the potential of allogeneic V\u03b42 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR\/IL-15 engineering. Nat Commun. 2023;14(1):6942.","journal-title":"Nat Commun"},{"issue":"8","key":"1745_CR152","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nri854","volume":"2","author":"M Kronenberg","year":"2002","unstructured":"Kronenberg M, Gapin L. The unconventional lifestyle of NKT cells. Nat Rev Immunol. 2002;2(8):557\u201368.","journal-title":"Nat Rev Immunol"},{"key":"1745_CR153","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1146\/annurev.immunol.25.022106.141711","volume":"25","author":"A Bendelac","year":"2007","unstructured":"Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol. 2007;25:297\u2013336.","journal-title":"Annu Rev Immunol"},{"issue":"14","key":"1745_CR154","doi-asserted-by":"publisher","first-page":"8395","DOI":"10.1073\/pnas.1332805100","volume":"100","author":"JL Matsuda","year":"2003","unstructured":"Matsuda JL, Gapin L, Baron JL, Sidobre S, Stetson DB, Mohrs M, et al. Mouse V alpha 14i natural killer T cells are resistant to cytokine polarization in vivo. Proc Natl Acad Sci U S A. 2003;100(14):8395\u2013400.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1745_CR155","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/mi.2009.99","volume":"2","author":"S Middendorp","year":"2009","unstructured":"Middendorp S, Nieuwenhuis EE. NKT cells in mucosal immunity. Mucosal Immunol. 2009;2(5):393\u2013402.","journal-title":"Mucosal Immunol"},{"issue":"11","key":"1745_CR156","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1016\/j.celrep.2018.02.058","volume":"22","author":"F Cortesi","year":"2018","unstructured":"Cortesi F, Delfanti G, Grilli A, Calcinotto A, Gorini F, Pucci F, et al. Bimodal CD40\/Fas-dependent crosstalk between iNKT cells and tumor-associated macrophages impairs prostate cancer progression. Cell Rep. 2018;22(11):3006\u201320.","journal-title":"Cell Rep"},{"issue":"12","key":"1745_CR157","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1084\/jem.20042280","volume":"201","author":"MJ Smyth","year":"2005","unstructured":"Smyth MJ, Wallace ME, Nutt SL, Yagita H, Godfrey DI, Hayakawa Y. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J Exp Med. 2005;201(12):1973\u201385.","journal-title":"J Exp Med"},{"issue":"5343","key":"1745_CR158","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1126\/science.278.5343.1623","volume":"278","author":"J Cui","year":"1997","unstructured":"Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, et al. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science. 1997;278(5343):1623\u201366.","journal-title":"Science"},{"issue":"18","key":"1745_CR159","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1182\/blood-2013-11-541235","volume":"124","author":"A Heczey","year":"2014","unstructured":"Heczey A, Liu D, Tian G, Courtney AN, Wei J, Marinova E, et al. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood. 2014;124(18):2824\u201333.","journal-title":"Blood"},{"issue":"4","key":"1745_CR160","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.ccell.2018.08.017","volume":"34","author":"A Rotolo","year":"2018","unstructured":"Rotolo A, Caputo VS, Holubova M, Baxan N, Dubois O, Chaudhry MS, et al. Enhanced Anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting. Cancer Cell. 2018;34(4):596\u2013610.","journal-title":"Cancer Cell"},{"issue":"12","key":"1745_CR161","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1002\/stem.2465","volume":"34","author":"D Yamada","year":"2016","unstructured":"Yamada D, Iyoda T, Vizcardo R, Shimizu K, Sato Y, Endo TA, et al. Efficient regeneration of human V\u03b124\u2009+ invariant natural killer T cells and their anti-tumor activity in vivo. Stem Cells. 2016;34(12):2852\u201360.","journal-title":"Stem Cells"},{"issue":"6","key":"1745_CR162","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1172\/JCI83476","volume":"126","author":"G Tian","year":"2016","unstructured":"Tian G, Courtney AN, Jena B, Heczey A, Liu D, Marinova E, et al. CD62L\u2009+\u2009NKT cells have prolonged persistence and antitumor activity in vivo. J Clin Invest. 2016;126(6):2341\u201355.","journal-title":"J Clin Invest"},{"issue":"11","key":"1745_CR163","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","volume":"26","author":"A Heczey","year":"2020","unstructured":"Heczey A, Courtney AN, Montalbano A, Robinson S, Liu K, Li M, et al. Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. Nat Med. 2020;26(11):1686\u201390.","journal-title":"Nat Med"},{"issue":"6","key":"1745_CR164","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1172\/JCI59535","volume":"122","author":"D Liu","year":"2012","unstructured":"Liu D, Song L, Wei J, Courtney AN, Gao X, Marinova E, et al. Il-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. J Clin Invest. 2012;122(6):2221\u201333.","journal-title":"J Clin Invest"},{"issue":"3","key":"1745_CR165","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41587-024-02226-y","volume":"43","author":"YR Li","year":"2024","unstructured":"Li YR, Zhou Y, Yu J, Kim YJ, Li M, Lee D, et al. Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method. Nat Biotechnol. 2024;43(3):329\u201344.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"1745_CR166","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56270-6","volume":"16","author":"YR Li","year":"2025","unstructured":"Li YR, Fang Y, Niu S, Zhu Y, Chen Y, Lyu Z, et al. Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies. Nat Commun. 2025;16(1):1248.","journal-title":"Nat Commun"},{"issue":"6","key":"1745_CR167","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.3324\/haematol.2023.284604","volume":"109","author":"F Locatelli","year":"2024","unstructured":"Locatelli F, Del Bufalo F, Quintarelli C. Allogeneic chimeric antigen receptor T cells for children with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia. Haematologica. 2024;109(6):1689\u201399.","journal-title":"Haematologica"},{"issue":"5","key":"1745_CR168","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.exphem.2009.01.010","volume":"37","author":"M Franceschetti","year":"2009","unstructured":"Franceschetti M, Pievani A, Borleri G, Vago L, Fleischhauer K, Golay J, et al. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol. 2009;37(5):616\u201328.","journal-title":"Exp Hematol"},{"issue":"12","key":"1745_CR169","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/j.bbmt.2017.07.005","volume":"23","author":"M Introna","year":"2017","unstructured":"Introna M, Lussana F, Algarotti A, Gotti E, Valgardsdottir R, Mic\u00f2 C, et al. Phase II study of sequential infusion of donor lymphocyte infusion and cytokine-induced killer cells for patients relapsed after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23(12):2070\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"1745_CR170","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.bbmt.2019.03.004","volume":"25","author":"M Merker","year":"2019","unstructured":"Merker M, Salzmann-Manrique E, Katzki V, Huenecke S, Bremm M, Bakhtiar S, et al. Clearance of hematologic malignancies by allogeneic cytokine-induced killer cell or donor lymphocyte infusions. Biol Blood Marrow Transplant. 2019;25(7):1281\u201392.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"1745_CR171","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1172\/JCI138473","volume":"130","author":"CF Magnani","year":"2020","unstructured":"Magnani CF, Gaipa G, Lussana F, Belotti D, Gritti G, Napolitano S, et al. Sleeping beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities. J Clin Invest. 2020;130(11):6021\u201333.","journal-title":"J Clin Invest"},{"issue":"9","key":"1745_CR172","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/sj.bmt.1705503","volume":"38","author":"M Introna","year":"2006","unstructured":"Introna M, Franceschetti M, Ciocca A, Borleri G, Conti E, Golay J, et al. Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant. 2006;38(9):621\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"1745_CR173","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00343","volume":"5","author":"B Omer","year":"2018","unstructured":"Omer B, Castillo PA, Tashiro H, Shum T, Huynh MTA, Cardenas M, et al. Chimeric antigen receptor signaling domains differentially regulate proliferation and native T cell receptor function in virus-specific T cells. Front Med Lausanne. 2018;5:343.","journal-title":"Front Med Lausanne"},{"issue":"26","key":"1745_CR174","doi-asserted-by":"publisher","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","volume":"121","author":"AM Leen","year":"2013","unstructured":"Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013;121(26):5113\u201323.","journal-title":"Blood"},{"issue":"7","key":"1745_CR175","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1182\/blood-2006-11-059139","volume":"110","author":"B Savoldo","year":"2007","unstructured":"Savoldo B, Rooney CM, Di Stasi A, Abken H, Hombach A, Foster AE, et al. Epstein barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of hodgkin disease. Blood. 2007;110(7):2620\u201330.","journal-title":"Blood"},{"issue":"17","key":"1745_CR176","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","volume":"122","author":"CR Cruz","year":"2013","unstructured":"Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013;122(17):2965\u201373.","journal-title":"Blood"},{"issue":"5","key":"1745_CR177","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s12185-021-03215-6","volume":"114","author":"X Wang","year":"2021","unstructured":"Wang X, Diamond DJ, Forman SJ, Nakamura R. Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine. Int J Hematol. 2021;114(5):544\u201353.","journal-title":"Int J Hematol"},{"issue":"13","key":"1745_CR178","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1158\/1078-0432.CCR-14-2998","volume":"21","author":"I Caruana","year":"2015","unstructured":"Caruana I, Weber G, Ballard BC, Wood MS, Savoldo B, Dotti G. K562-derived whole-cell vaccine enhances antitumor responses of CAR-redirected virus-specific cytotoxic T lymphocytes in vivo. Clin Cancer Res. 2015;21(13):2952\u201362.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1745_CR179","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nm827","volume":"9","author":"RJ Brentjens","year":"2003","unstructured":"Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. 2003;9(3):279\u201386.","journal-title":"Nat Med"},{"issue":"2","key":"1745_CR180","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.ymthe.2019.12.009","volume":"28","author":"FD Bushman","year":"2020","unstructured":"Bushman FD. Retroviral insertional mutagenesis in humans: evidence for four genetic mechanisms promoting expansion of cell clones. Mol Ther. 2020;28(2):352\u20136.","journal-title":"Mol Ther"},{"issue":"1","key":"1745_CR181","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1186\/s12967-022-03729-5","volume":"20","author":"L Shao","year":"2022","unstructured":"Shao L, Shi R, Zhao Y, Liu H, Lu A, Ma J, et al. Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products. J Transl Med. 2022;20(1):514.","journal-title":"J Transl Med"},{"issue":"21","key":"1745_CR182","doi-asserted-by":"publisher","first-page":"5104","DOI":"10.1182\/blood-2008-11-191049","volume":"113","author":"RE Throm","year":"2009","unstructured":"Throm RE, Ouma AA, Zhou S, Chandrasekaran A, Lockey T, Greene M, et al. Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood. 2009;113(21):5104\u201310.","journal-title":"Blood"},{"issue":"132","key":"1745_CR183","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003761","volume":"4","author":"J Scholler","year":"2012","unstructured":"Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med. 2012;4(132):132ra53.","journal-title":"Sci Transl Med"},{"issue":"1","key":"1745_CR184","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1182\/blood.2022015728","volume":"140","author":"DHM Steffin","year":"2022","unstructured":"Steffin DHM, Muhsen IN, Hill LC, Ramos CA, Ahmed N, Hegde M, et al. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022;140(1):16\u201324.","journal-title":"Blood"},{"issue":"9","key":"1745_CR185","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/gt.2011.40","volume":"18","author":"Z Jin","year":"2011","unstructured":"Jin Z, Maiti S, Huls H, Singh H, Olivares S, M\u00e1t\u00e9s L, et al. The hyperactive sleeping beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor. Gene Ther. 2011;18(9):849\u201356.","journal-title":"Gene Ther"},{"key":"1745_CR186","first-page":"646","volume":"20","author":"H Kubo","year":"2021","unstructured":"Kubo H, Yagyu S, Nakamura K, Yamashima K, Tomida A, Kikuchi K, et al. Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcoma. Mol Ther. 2021;20:646\u201358.","journal-title":"Mol Ther"},{"issue":"9","key":"1745_CR187","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.tibtech.2015.06.009","volume":"33","author":"LE Woodard","year":"2015","unstructured":"Woodard LE, Wilson MH. PiggyBac-ing models and new therapeutic strategies. Trends Biotechnol. 2015;33(9):525\u201333.","journal-title":"Trends Biotechnol"},{"issue":"2","key":"1745_CR188","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","volume":"2","author":"GL Beatty","year":"2014","unstructured":"Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014;2(2):112\u201320.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1745_CR189","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1021\/acs.nanolett.1c02503","volume":"22","author":"MM Billingsley","year":"2022","unstructured":"Billingsley MM, Hamilton AG, Mai D, Patel SK, Swingle KL, Sheppard NC, et al. Orthogonal design of experiments for optimization of lipid nanoparticles for mRNA engineering of CAR T cells. Nano Lett. 2022;22(1):533\u201342.","journal-title":"Nano Lett"},{"issue":"6","key":"1745_CR190","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.jcyt.2023.01.005","volume":"25","author":"K Si","year":"2023","unstructured":"Si K, Dai Z, Li Z, Ye Z, Ding B, Feng S, et al. Engineered exosome-mediated messenger RNA and single-chain variable fragment delivery for human chimeric antigen receptor T-cell engineering. Cytotherapy. 2023;25(6):615\u201324.","journal-title":"Cytotherapy"},{"issue":"16","key":"1745_CR191","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf1333","volume":"7","author":"M Bozza","year":"2021","unstructured":"Bozza M, De Roia A, Correia MP, Berger A, Tuch A, Schmidt A, et al. A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells. Sci Adv. 2021;7(16):eabf1333.","journal-title":"Sci Adv"},{"issue":"8","key":"1745_CR192","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nnano.2017.57","volume":"12","author":"TT Smith","year":"2017","unstructured":"Smith TT, Stephan SB, Moffett HF, McKnight LE, Ji W, Reiman D, et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat Nanotechnol. 2017;12(8):813\u201320.","journal-title":"Nat Nanotechnol"},{"issue":"Suppl 1","key":"1745_CR193","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1182\/blood-2020-138984","volume":"136","author":"GJ Roboz","year":"2020","unstructured":"Roboz GJ, DeAngelo DJ, Sallman DA, Guzman ML, Desai P, Kantarjian HM, et al. Ameli-01: phase i, open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), administered in patients with relapsed\/refractory acute myeloid leukemia. Blood. 2020;136(Suppl 1):41\u20132.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1745_CR194","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2020-138594","volume":"136","author":"N Jain","year":"2020","unstructured":"Jain N, Roboz GJ, Konopleva M, Liu H, Jabbour E, Poirot C, et al. Preliminary results of Balli-01: a phase I study of UCART22 (allogeneic engineered T-cells expressing anti-CD22 chimeric antigen receptor) in adult patients with relapsed or refractory (R\/R) CD22\u2009+\u2009B-cell acute lymphoblastic leukemia (B-ALL). Blood. 2020;136(Suppl 1):7\u20138.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1745_CR195","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1182\/blood-2022-157950","volume":"140","author":"CLBM Korst","year":"2022","unstructured":"Korst CLBM, Bruins WSC, Cosovic M, Verkleij CPM, Twickler I, Le Clerre D, et al. Preclinical activity of allogeneic CS1-specific CAR T-cells (UCARTCS1) in multiple myeloma. Blood. 2022;140(Suppl 1):4215\u20136.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1745_CR196","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1182\/blood-2023-186570","volume":"142","author":"JS Abramson","year":"2023","unstructured":"Abramson JS, Ramakrishnan A, Pierola AA, Braunschweig I, Cartron G, Thieblemont C, et al. Preliminary results of Nathali-01: a first-in-human phase I\/IIa study of UCART20x22, a dual allogeneic CAR-T cell product targeting CD20 and CD22, in relapsed or refractory (R\/R) non-Hodgkin lymphoma (NHL). Blood. 2023;142(Suppl 1):2110\u20132110.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1745_CR197","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1182\/blood-2021-146038","volume":"138","author":"SS Neelapu","year":"2021","unstructured":"Neelapu SS, Nath R, Munoz J, Tees M, Miklos DB, Frank MJ, et al. ALPHA study: ALLO-501 produced deep and durable responses in patients with relapsed\/refractory non-Hodgkin\u2019s lymphoma comparable to autologous CAR T. Blood. 2021;138(Suppl 1):3878\u20133878.","journal-title":"Blood"},{"issue":"2","key":"1745_CR198","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","volume":"29","author":"S Mailankody","year":"2023","unstructured":"Mailankody S, Matous JV, Chhabra S, Liedtke M, Sidana S, Oluwole OO, et al. Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat Med. 2023;29(2):422\u20139.","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"1745_CR199","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1182\/blood-2023-172780","volume":"142","author":"AP Jallouk","year":"2023","unstructured":"Jallouk AP, Ge Z, Kaimal V, Furmanak T, Sommer C, Lauron EJ, et al. Cellular mechanisms affecting allogeneic CAR T cell expansion and rejection in large B-cell lymphoma. Blood. 2023;142(Suppl 1):4832.","journal-title":"Blood"},{"issue":"8","key":"1745_CR200","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1182\/bloodadvances.2021006232","volume":"6","author":"Y Guo","year":"2022","unstructured":"Guo Y, Tong C, Su L, Zhang W, Jia H, Liu Y, et al. CRISPR\/Cas 9 genome-edited universal CAR T cells in patients with relapsed\/refractory lymphoma. Blood Adv. 2022;6(8):2695\u20139.","journal-title":"Blood Adv"},{"key":"1745_CR201","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/01.HS9.0000844368.41871.e3","volume":"6","author":"S Li","year":"2022","unstructured":"Li S, Yuan Z, Liu L, Li Y, Martina S, Liu J, et al. P370: early results of a safety and efficacy study of allogeneic TRUUCAR\u2122 GC502 in patients with relapsed\/ refractory B-cell acute lymphoblastic leukemia (R\/R B-ALL). HemaSphere. 2022;6:270\u20131.","journal-title":"HemaSphere"},{"key":"1745_CR202","doi-asserted-by":"publisher","unstructured":"Wu Z, Shi J, Lamao Q, Qiu Y, Yang J, Liu Y et al. Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy. Cell. 2025:S0092-8674(25)00910-9. Online ahead of print. https:\/\/doi.org\/10.1016\/j.cell.2025.07.046","DOI":"10.1016\/j.cell.2025.07.046"},{"issue":"Suppl 1","key":"1745_CR203","doi-asserted-by":"publisher","first-page":"9457","DOI":"10.1182\/blood-2022-168128","volume":"140","author":"S O\u2019Brien","year":"2022","unstructured":"O\u2019Brien S, Nastoupil LJ, Essell J, Dsouza L, Hart D, Matsuda E, et al. A First-in-Human phase 1, Multicenter, Open-Label study of CB-010, a Next-Generation CRISPR-Edited allogeneic Anti-CD19 CAR-T cell therapy with a PD-1 Knockout, in patients with Relapsed\/Refractory B cell Non-Hodgkin lymphoma (ANTLER study). Blood. 2022;140(Suppl 1):9457\u20138.","journal-title":"Blood"},{"issue":"Suppl 16","key":"1745_CR204","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS6586","volume":"42","author":"NG Daver","year":"2024","unstructured":"Daver NG, Maiti A, Sallman DA, Roboz GJ, Solh MM, Milano F, et al. A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed\/refractory acute myeloid leukemia (AMplify). J Clin Oncol. 2024;42(Suppl 16):TPS6586.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"1745_CR205","doi-asserted-by":"publisher","first-page":"10303","DOI":"10.1182\/blood-2022-166432","volume":"140","author":"JP McGuirk","year":"2022","unstructured":"McGuirk JP, Tam CS, Kr\u00f6ger N, Riedell PA, Murthy HS, Joy Ho P, et al. CTX110 allogeneic CRISPR-Cas 9-Engineered CAR T cells in patients (Pts) with relapsed or refractory (R\/R) large B-Cell lymphoma (LBCL): results from the phase 1 dose escalation carbon study. Blood. 2022;140(Suppl 1):10303\u20136.","journal-title":"Blood"},{"issue":"1","key":"1745_CR206","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S1470-2045(24)00508-4","volume":"26","author":"SP Iyer","year":"2025","unstructured":"Iyer SP, Sica RA, Ho PJ, Prica A, Zain J, Foss FM, et al. Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas 9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study. Lancet Oncol. 2025;26(1):110\u201322.","journal-title":"Lancet Oncol"},{"issue":"Suppl 7","key":"1745_CR207","doi-asserted-by":"publisher","first-page":"ND02","DOI":"10.1158\/1538-7445.AM2023-ND02","volume":"83","author":"JA Terrett","year":"2023","unstructured":"Terrett JA, Kalaitzidis D, Dequeant M-L, Karnik S, Ghonime M, Guo C, et al. Abstract ND02: CTX112 and CTX131: Next-generation CRISPR\/Cas 9-engineered allogeneic (allo) CAR T cells incorporating novel edits that increase potency and efficacy in the treatment of lymphoid and solid tumors. Cancer Res. 2023;83(Suppl 7):ND02.","journal-title":"Cancer Res"},{"issue":"Suppl 15","key":"1745_CR208","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1200\/JCO.2020.38.15_suppl.3013","volume":"38","author":"X Wang","year":"2020","unstructured":"Wang X, Li S, Gao L, Yuan Z, Wu K, Liu L, et al. Safety and efficacy results of GC027: the first-in-human, universal CAR-T cell therapy for adult relapsed\/refractory T-cell acute lymphoblastic leukemia (r\/r T-ALL). J Clin Oncol. 2020;38(Suppl 15):3013.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1745_CR209","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","volume":"27","author":"Y Hu","year":"2021","unstructured":"Hu Y, Zhou Y, Zhang M, Ge W, Li Y, Yang L, et al. CRISPR\/Cas 9-engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2021;27(10):2764\u201372.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"1745_CR210","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1182\/blood-2021-152985","volume":"138","author":"X Yuan","year":"2021","unstructured":"Yuan X, Clarke R, Lai Y, Chang CW, Yang BH, Hsia G, et al. Clinical manufacture of FT819: use of a clonal multiplexed-engineered master induced pluripotent stem cell line to mass produce off-the-shelf CAR t-cell therapy. Blood. 2021;138(Suppl 1):1766.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1745_CR211","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1182\/blood-2023-178723","volume":"142","author":"A Ghobadi","year":"2023","unstructured":"Ghobadi A, Aldoss I, Maude SL, Bhojwani D, Wayne AS, Bajel A, et al. Phase 1\/2 dose-escalation\/dose-expansion study of anti-CD7 allogeneic CAR-T cells (WU-CART-007) in relapsed or refractory (R\/R) T-cell acute lymphoblastic leukemia\/ lymphoblastic lymphoma (T-ALL\/LBL). Blood. 2023;142(Suppl 1):770.","journal-title":"Blood"},{"issue":"Suppl 7","key":"1745_CR212","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1158\/1538-7445.AM2023-4095","volume":"83","author":"A Ehninger","year":"2023","unstructured":"Ehninger A, Spehr J, Loff S, Langer A, Riewaldt J, Reinhardt J, et al. Abstract 4095: preclinical characterization of switchable allogeneic chimeric antigen receptor T cells to support first in human clinical study in CD123-positive hematologic and lymphatic malignancies. Cancer Res. 2023;83(Suppl 7):4095.","journal-title":"Cancer Res"},{"issue":"Suppl 1","key":"1745_CR213","doi-asserted-by":"publisher","first-page":"4588","DOI":"10.1182\/blood-2022-165311","volume":"140","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Jayawardena T, Yu L, Hallman J, Schmittling R, Cuneo E, et al. Effective cell dose and functional attributes of Azercabtagene Zapreleucel (azer-cel; PBCAR0191) associate with allogeneic CAR t-cell safety and efficacy in patients with relapsed\/refractory B-cell lymphoma. Blood. 2022;140(Suppl 1):4588\u20139.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1745_CR214","doi-asserted-by":"publisher","first-page":"4828","DOI":"10.1182\/blood-2024-207459","volume":"144","author":"B Dholaria","year":"2024","unstructured":"Dholaria B, Shune LO, Kocoglu MH, Kin A, Ramakrishnan A, Malek E, et al. A phase 1 study of P-BCMA-ALLO1, a non-viral, allogeneic BCMA directed CAR-T in relapsed\/refractory multiple myeloma (RRMM): results from optimized lymphodepletion cohort. Blood. 2024;144(Suppl 1):4828.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1745_CR215","doi-asserted-by":"publisher","first-page":"100151","DOI":"10.1016\/j.iotech.2022.100151","volume":"16","author":"D Oh","year":"2022","unstructured":"Oh D, Henry J, Baranda JC, Dumbrava EE, Cohen E, Eskew JD, et al. Poseida therapeutics: development of an allogeneic CAR-T targeting MUC1-C (MUC1, cell surface associated, C-terminal) for epithelial derived tumors. Immuno-Oncology Technol. 2022;16(Suppl 1):100151.","journal-title":"Immuno-Oncology Technol"},{"issue":"Suppl 10","key":"1745_CR216","doi-asserted-by":"publisher","first-page":"x11","DOI":"10.1093\/annonc\/mdy485.002","volume":"29","author":"S Chen","year":"2018","unstructured":"Chen S, Lin Y, Zhong S, An H, Lu Y, Yin M, et al. Anti-MUC1 CAR-T cells combined with PD-1 knockout engineered T cells for patients with non-small cell lung cancer (NSCLC): A pilot study. Ann Oncol. 2018;29(Suppl 10):x11\u20136.","journal-title":"Ann Oncol"},{"issue":"Suppl 16","key":"1745_CR217","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1200\/JCO.2024.42.16_suppl.1089","volume":"42","author":"YG Lin","year":"2024","unstructured":"Lin YG, Yin H, Zhou C, Zhou L, Zeng Y, Yao H. Phase I clinical trial of MUC1-targeted CAR-T cells with PD-1-knockout in the treatment of advanced breast cancer. J Clin Oncol. 2024;42(Suppl 16):1089.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1745_CR218","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","volume":"18","author":"Z Wang","year":"2021","unstructured":"Wang Z, Li N, Feng K, Chen M, Zhang Y, Liu Y, et al. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. Cell Mol Immunol. 2021;18(9):2188\u201398.","journal-title":"Cell Mol Immunol"},{"issue":"Suppl 15","key":"1745_CR219","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1200\/JCO.2020.38.15_suppl.3038","volume":"38","author":"Z Wang","year":"2020","unstructured":"Wang Z, Chen M, Zhang Y, Liu Y, Yang Q, Nie J, et al. Phase I study of CRISPR-engineered CAR-T cells with PD-1 inactivation in treating mesothelin-positive solid tumors. J Clin Oncol. 2020;38(Suppl 15):3038.","journal-title":"J Clin Oncol"},{"issue":"Suppl 7","key":"1745_CR220","doi-asserted-by":"publisher","first-page":"CT002","DOI":"10.1158\/1538-7445.AM2024-CT002","volume":"84","author":"SK Pal","year":"2024","unstructured":"Pal SK, Tran B, Haanen JB, Hurwitz M, Sacher A, Agarwal N, et al. Abstract CT002: CTX130 allogeneic CRISPR-Cas 9-engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: long-term follow-up and translational data from the phase 1 COBALT-RCC study. Cancer Res. 2024;84(Suppl 7):CT002.","journal-title":"Cancer Res"},{"issue":"Suppl 16","key":"1745_CR221","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2676","volume":"42","author":"SK Pal","year":"2024","unstructured":"Pal SK, Reimers MA, Garmezy B, Xu W, Hoimes CJ, Weinstein M, et al. A phase 1\/2, open-label, multicenter, dose escalation and cohort expansion study of the safety and efficacy of anti-CD70 allogeneic CRISPR-Cas 9\u2013engineered T cells (CTX131) in adult patients with relapsed or refractory solid tumors. J Clin Oncol. 2024;42(Suppl 16):TPS2676.","journal-title":"J Clin Oncol"},{"issue":"Suppl 8","key":"1745_CR222","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-CT011","volume":"83","author":"S Srour","year":"2023","unstructured":"Srour S, Kotecha R, Curti B, Chahoud J, Drakaki A, Tang L, et al. Abstract CT011: a phase 1 multicenter study (TRAVERSE) evaluating the safety and efficacy of ALLO-316 following conditioning regimen in Pts with advanced or metastatic clear cell renal cell carcinoma (ccRCC). Cancer Res. 2023;83(Suppl 8):CT011.","journal-title":"Cancer Res"},{"issue":"Suppl 1","key":"1745_CR223","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1182\/blood-2023-182430","volume":"142","author":"B Dholaria","year":"2023","unstructured":"Dholaria B, Kocoglu MH, Kin A, Asch AS, Ramakrishnan A, Bachier C, et al. Early safety results of P-BCMA-ALLO1, a fully allogeneic chimeric antigen receptor T-cell (CAR-T), in patients with relapsed \/ refractory multiple myeloma (RRMM). Blood. 2023;142(Suppl 1):3479.","journal-title":"Blood"},{"issue":"3","key":"1745_CR224","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","volume":"130","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH, et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017;130(3):285\u201396.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1745_CR225","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1182\/blood-2021-148500","volume":"138","author":"J Ge","year":"2021","unstructured":"Ge J, Yang C, Sun J, Chen J, Qiu S, Yin WJ, et al. Preclinical results of an allogeneic, universal CD19\/CD7-targeting CAR-T cell therapy (GC502) for B cell malignancies. Blood. 2021;138(Suppl 1):1722.","journal-title":"Blood"},{"issue":"7","key":"1745_CR226","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1158\/2326-6066.CIR-22-0910","volume":"11","author":"B Aranda-Orgilles","year":"2023","unstructured":"Aranda-Orgilles B, Chion-Sotinel I, Skinner J, Grudman S, Mumford B, Dixon C, et al. Preclinical evidence of an allogeneic dual CD20xCD22 CAR to target a broad spectrum of patients with B-cell malignancies. Cancer Immunol Res. 2023;11(7):946\u201361.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1745_CR227","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12943-025-02386-8","volume":"24","author":"SS Azeez","year":"2025","unstructured":"Azeez SS, Yashooa RK, Smail SW, Salihi A, Ali AS, Mamand S, Janson C. Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives. Mol Cancer. 2025;24(1):191.","journal-title":"Mol Cancer"},{"key":"1745_CR228","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41698-023-00492-8","volume":"8","author":"S Wang","year":"2024","unstructured":"Wang S, Wang J, Chen Z, Luo J, Guo W, Sun L, et al. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. Npj Precis Oncol. 2024;8:1\u201319.","journal-title":"Npj Precis Oncol"},{"key":"1745_CR229","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1042\/BST20150291","volume":"44","author":"OO Yeku","year":"2016","unstructured":"Yeku OO, Brentjens RJ. Armored CAR t-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR t-cell anti-tumour efficacy. Biochem Soc Trans. 2016;44:412\u20138.","journal-title":"Biochem Soc Trans"},{"key":"1745_CR230","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","volume":"637","author":"D Steffin","year":"2025","unstructured":"Steffin D, Ghatwai N, Montalbano A, Rathi P, Courtney AN, Arnett AB, et al. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025;637:940\u20136.","journal-title":"Nature"},{"key":"1745_CR231","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-023-01668-1","volume":"9","author":"W Zhu","year":"2024","unstructured":"Zhu W, Zhang Z, Chen J, Chen X, Huang L, Zhang X, et al. A novel engineered IL-21 receptor arms T-cell receptor-engineered T cells (TCR-T cells) against hepatocellular carcinoma. Signal Transduct Target Ther. 2024;9:1\u201316.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"1745_CR232","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065424","volume":"24","author":"J Wang","year":"2023","unstructured":"Wang J, Wang Y, Pan H, Zhao L, Yang X, Liang Z, et al. Chemokine receptors CCR6 and PD1 blocking ScFv E27 enhances anti-EGFR CAR-T therapeutic efficacy in a preclinical model of human non-small cell lung carcinoma. Int J Mol Sci. 2023;24(6):1.","journal-title":"Int J Mol Sci"},{"key":"1745_CR233","doi-asserted-by":"publisher","unstructured":"Ma T, Renz BW, Ilmer M, Koch D, Yang Y, Werner J, et al. Myeloid-derived suppressor cells in solid tumors. Cells. 2022;11(2):310. https:\/\/doi.org\/10.3390\/cells11020310.","DOI":"10.3390\/cells11020310"},{"key":"1745_CR234","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines4030028","volume":"4","author":"B Chaudhary","year":"2016","unstructured":"Chaudhary B, Elkord E. Regulatory t cells in the tumor microenvironment and cancer progression: role and therapeutic targeting. Vaccines. 2016;4:28.","journal-title":"Vaccines"},{"key":"1745_CR235","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.omto.2021.03.014","volume":"21","author":"X Chen","year":"2021","unstructured":"Chen X, Yang S, Li S, Qu Y, Wang HY, Liu J, et al. Secretion of bispecific protein of anti-PD-1 fused with TGF-beta trap enhances antitumor efficacy of CAR-T cell therapy. Mol Ther Oncolytics. 2021;21:144\u201357.","journal-title":"Mol Ther Oncolytics"},{"issue":"4","key":"1745_CR236","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133977","volume":"5","author":"N Tang","year":"2020","unstructured":"Tang N, Cheng C, Zhang X, Qiao M, Li N, Mu W, et al. TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight. 2020;5(4):e133977.","journal-title":"JCI Insight"},{"issue":"2","key":"1745_CR237","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.ymthe.2024.12.014","volume":"33","author":"S Zheng","year":"2025","unstructured":"Zheng S, Che X, Zhang K, Bai Y, Deng H. Potentiating CAR-T cell function in the immunosuppressive tumor microenvironment by inverting the TGF-\u03b2 signal. Mol Ther. 2025;33(2):688\u2013702.","journal-title":"Mol Ther"},{"key":"1745_CR238","doi-asserted-by":"publisher","first-page":"7707","DOI":"10.1002\/jcb.27120","volume":"119","author":"H Zhu","year":"2018","unstructured":"Zhu H, Zhang S. Hypoxia inducible factor-1\u03b1\/vascular endothelial growth factor signaling activation correlates with response to radiotherapy and its inhibition reduces hypoxia-induced angiogenesis in lung cancer. J Cell Biochem. 2018;119:7707\u201318.","journal-title":"J Cell Biochem"},{"key":"1745_CR239","doi-asserted-by":"publisher","first-page":"100227","DOI":"10.1016\/j.xcrm.2021.100227","volume":"2","author":"P Kosti","year":"2021","unstructured":"Kosti P, Opzoomer JW, Larios-Martinez KI, Henley-Smith R, Scudamore CL, Okesola M, et al. Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors. Cell Rep Med. 2021;2:100227.","journal-title":"Cell Rep Med"},{"key":"1745_CR240","doi-asserted-by":"publisher","first-page":"828875","DOI":"10.3389\/fimmu.2022.828875","volume":"13","author":"R Abou Khouzam","year":"2022","unstructured":"Abou Khouzam R, Zaarour RF, Brodaczewska K, Azakir B, Venkatesh GH, Thiery J, et al. The effect of hypoxia and hypoxia-Associated pathways in the regulation of antitumor response: friends or foes? Front Immunol. 2022;13:828875.","journal-title":"Front Immunol"},{"key":"1745_CR241","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1038\/s41467-021-23331-5","volume":"12","author":"L Giuffrida","year":"2021","unstructured":"Giuffrida L, Sek K, Henderson MA, Lai J, Chen AXY, Meyran D, et al. CRISPR\/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. Nat Commun. 2021;12:3236.","journal-title":"Nat Commun"},{"issue":"6","key":"1745_CR242","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cmet.2025.04.008","volume":"37","author":"C Niu","year":"2025","unstructured":"Niu C, Wei H, Pan X, Wang Y, Song H, Li C, et al. Foxp3 confers long-term efficacy of chimeric antigen receptor-T cells via metabolic reprogramming. Cell Metab. 2025;37(6):1426\u201341.","journal-title":"Cell Metab"},{"key":"1745_CR243","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","volume":"31","author":"KG Anderson","year":"2017","unstructured":"Anderson KG, Stromnes IM, Greenberg PD. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell. 2017;31:311\u201325.","journal-title":"Cancer Cell"},{"key":"1745_CR244","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","volume":"77","author":"R Lugano","year":"2019","unstructured":"Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci. 2019;77:1745\u201370.","journal-title":"Cell Mol Life Sci"},{"issue":"10","key":"1745_CR245","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1158\/0008-5472.CAN-12-4354","volume":"73","author":"Y Huang","year":"2013","unstructured":"Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 2013;73(10):2943\u20138.","journal-title":"Cancer Res"},{"key":"1745_CR246","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/eji.201948457","volume":"50","author":"G Liu","year":"2020","unstructured":"Liu G, Rui W, Zheng H, Huang D, Yu F, Zhang Y, et al. CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma. Eur J Immunol. 2020;50:712\u201324.","journal-title":"Eur J Immunol"},{"key":"1745_CR247","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3390\/cancers13030469","volume":"13","author":"JC L\u00f3pez-Gil","year":"2021","unstructured":"L\u00f3pez-Gil JC, Martin-Hijano L, Hermann PC, Sainz B. The CXCL12 crossroads in cancer stem cells and their niche. Cancers. 2021;13:469.","journal-title":"Cancers"},{"key":"1745_CR248","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00262-024-03909-w","volume":"74","author":"Y Tian","year":"2025","unstructured":"Tian Y, Zhang L, Ping Y, Zhang Z, Yao C, Shen C, et al. CCR5 and IL-12 co-expression in CAR T cells improves antitumor efficacy by reprogramming tumor microenvironment in solid tumors. Cancer Immunol Immunother CII. 2025;74:55.","journal-title":"Cancer Immunol Immunother CII"},{"key":"1745_CR249","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2159-8290.CD-24-0002","volume":"14","author":"J Prakash","year":"2024","unstructured":"Prakash J, Shaked Y. The interplay between extracellular matrix remodeling and cancer therapeutics. Cancer Discov. 2024;14:1375\u201388.","journal-title":"Cancer Discov"},{"issue":"2","key":"1745_CR250","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200817","volume":"32","author":"L Zhou","year":"2024","unstructured":"Zhou L, Li Y, Zheng D, Zheng Y, Cui Y, Qin L, et al. Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma. Mol Ther Oncol. 2024;32(2):200817.","journal-title":"Mol Ther Oncol"},{"issue":"5","key":"1745_CR251","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nm.3833","volume":"21","author":"I Caruana","year":"2015","unstructured":"Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med. 2015;21(5):524\u20139.","journal-title":"Nat Med"},{"issue":"6","key":"1745_CR252","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3390\/jcm9061894","volume":"9","author":"D Bebnowska","year":"2020","unstructured":"Bebnowska D, Grywalska E, Niedzwiedzka-Rystwej P, Sosnowska-Pasiarska B, Smok-Kalwat J, Pasiarski M, et al. CAR-T cell Therapy-An overview of targets in gastric cancer. J Clin Med. 2020;9(6):1894.","journal-title":"J Clin Med"},{"issue":"2","key":"1745_CR253","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","volume":"6","author":"A Morello","year":"2016","unstructured":"Morello A, Sadelain M, Adusumilli PS. Mesothelin-targeted cars: driving T cells to solid tumors. Cancer Discov. 2016;6(2):133\u201346.","journal-title":"Cancer Discov"},{"issue":"2","key":"1745_CR254","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.humimm.2020.12.002","volume":"82","author":"G Liu","year":"2021","unstructured":"Liu G, Zhang Q, Li D, Zhang L, Gu Z, Liu J, et al. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells. Hum Immunol. 2021;82(2):130\u20138.","journal-title":"Hum Immunol"},{"issue":"Suppl 16","key":"1745_CR255","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1200\/JCO.2024.42.16_suppl.2501","volume":"42","author":"CS Qi","year":"2024","unstructured":"Qi CS, Liu C, Gong JF, Li J, Liu D, Wang XC, et al. Claudin18.2-targeted chimeric antigen receptor T cell-therapy for patients with gastrointestinal cancers: final results of CT041-CG4006 phase 1 trial. J Clin Oncol. 2024;42(Suppl 16):2501.","journal-title":"J Clin Oncol"},{"issue":"Suppl 16","key":"1745_CR256","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1200\/JCO.2024.42.16_suppl.2518","volume":"42","author":"CS Qi","year":"2024","unstructured":"Qi CS, Liu C, Li J, Gong JF, Wang XC, Wang ZH, et al. Phase I study of GUCY2C CAR-T therapy IM96 in patients with metastatic colorectal cancer. J Clin Oncol. 2024;42(Suppl 16):2518.","journal-title":"J Clin Oncol"},{"issue":"Suppl 16","key":"1745_CR257","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1200\/JCO.2024.42.16_suppl.4019","volume":"42","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Fu Q, Cao W, Wang H, Xu XY, Huang JQ, et al. Phase I study of C-CAR031, a GPC3-specific TGF\u03b2RIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2024;42(Suppl 16):4019.","journal-title":"J Clin Oncol"},{"issue":"Suppl 16","key":"1745_CR258","doi-asserted-by":"publisher","first-page":"6112","DOI":"10.1200\/JCO.2024.42.16_suppl.6112","volume":"42","author":"SA Srour","year":"2024","unstructured":"Srour SA, Villaflor VM, Lorch JH, Zafereo ME, Gupta S, Hu MIN, et al. Safety and efficacy of AIC100 chimeric antigen receptor (CAR) T-cell therapy in patients with advanced thyroid cancers: results from the phase 1 study. J Clin Oncol. 2024;42(Suppl 16):6112.","journal-title":"J Clin Oncol"},{"issue":"23","key":"1745_CR259","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adu4417","volume":"11","author":"QH Sodji","year":"2025","unstructured":"Sodji QH, Shea A, Cappabianca D, Forsberg MH, Eickhoff JC, Idrissou MB, et al. Low-dose radiation by radiopharmaceutical therapy enhances GD2 TRAC-CAR T cell efficacy in localized neuroblastoma. Sci Adv. 2025;11(23):eadu4417.","journal-title":"Sci Adv"},{"key":"1745_CR260","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101082","volume":"74","author":"Y Huang","year":"2024","unstructured":"Huang Y, Qin Y, He Y, Qiu D, Zheng Y, Wei J, et al. Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies. Drug Resist Updat. 2024;74:101082.","journal-title":"Drug Resist Updat"},{"issue":"3","key":"1745_CR261","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197\u2013218.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1745_CR262","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01625-7","volume":"17","author":"K Ai","year":"2024","unstructured":"Ai K, Liu B, Chen X, Huang C, Yang L, Zhang W, et al. Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies. J Hematol Oncol. 2024;17(1):105.","journal-title":"J Hematol Oncol"},{"issue":"6753","key":"1745_CR263","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL Hunter","year":"2025","unstructured":"Hunter TL, Bao Y, Zhang Y, Matsuda D, Riener R, Wang A, et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science. 2025;388(6753):1311\u20137.","journal-title":"Science"},{"issue":"2","key":"1745_CR264","doi-asserted-by":"publisher","DOI":"10.1016\/j.celbio.2025.100011","volume":"1","author":"Y Wang","year":"2025","unstructured":"Wang Y, Yang M, Zhang BY, Zhao G, Zhou SK, Lu ZD, et al. Leveraging T cell-specific fusogenicity of HIV for in vivo mRNA delivery to produce human CAR-T cells. Cell Biomater. 2025;1(2):100011.","journal-title":"Cell Biomater"},{"issue":"3","key":"1745_CR265","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.scib.2023.11.055","volume":"69","author":"G Zhao","year":"2024","unstructured":"Zhao G, Zhang Y, Xu CF, Wang J. In vivo production of CAR-T cells using virus-mimetic fusogenic nanovesicles. Sci Bull. 2024;69(3):354\u201366.","journal-title":"Sci Bull"},{"key":"1745_CR266","doi-asserted-by":"publisher","unstructured":"Zhang Z, Ma B, Li B, Li Z, Gao M, Zhao H, et al. Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging. Cell Rep Med. 2025;6(7):102209. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102209","DOI":"10.1016\/j.xcrm.2025.102209"},{"issue":"10500","key":"1745_CR267","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","volume":"406","author":"J Xu","year":"2025","unstructured":"Xu J, Liu L, Parone P, Xie W, Sun C, Chen Z, et al. In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma. Lancet. 2025;406(10500):228\u201331.","journal-title":"Lancet"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01745-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01745-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01745-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T15:03:23Z","timestamp":1761318203000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01745-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":267,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1745"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01745-8","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}